** Shares in Ion Beam Applications IBAB.BR fall about 10%
after the company published its results in the first half, with
group REBIT turning to negative on backlog conversion miss
** The Belgian proton therapy company posts H1 REBIT loss of
20.3 million euros ($22.12 million) versus profit of 4.6 million
euros last year, which is affected by the backlog conversion
miss and preparation of growth investments for the next quarters
** The company also confirmed its FY guidance, expecting
strong improvement in H2
** KBC Securities says results are "well below" its
expectations
** "We think it will be difficult for IBA to reach our FY23
sales estimate of 456 million euros, meaning we will likely have
to revise our estimates", KBC Securities says
** The analysts from ING doubt the short term sentiment will
"prevail" over the brighter long term outlook, which is
"tainted" by macro fears
** Including Thursday's fall the stock has dropped by 26.61%
YTD, and shares are on track for its worst day since mid-March
2020
** The stock touches lowest price in about 34 months
($1 = 0.9179 euros)
(Reporting by Lina Golovnya)
((lina.golovnya@thomsonreuters.com))